Company profile: Syros
1.1 - Company Overview
Company description
- Provider of a gene control platform that systematically analyzes regulatory regions of the genome to develop small-molecule medicines that control gene expression, and developer of oral therapeutics including tamibarotene (selective RARΞ± agonist) in clinical development for genomically defined HR-MDS and AML, and previously clinical assets SY-2101 (oral arsenic trioxide for APL) and SY-5609 (CDK7 inhibitor for pancreatic cancer).
Products and services
- Gene Control Platform: A genomics-driven platform that systematically analyzes regulatory regions of the genome to engineer small-molecule medicines controlling expression of genes critical to a given cell
- Tamibarotene: A clinical-stage, oral selective retinoic acid receptor alpha (RARΞ±) agonist in development for genomically defined subsets of higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML)
- SY-2101: A novel oral arsenic trioxide (ATO) form previously in clinical development for patients with acute promyelocytic leukemia (APL), enabling APL treatment via oral ATO administration
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Syros
Synlogic
HQ: United States
Website
- Description: Provider of synthetic biotic medicines designed to perform metabolic functions to treat diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Synlogic company profile β
Genomics
HQ: United Kingdom
Website
- Description: Provider of health-tech solutions leveraging genetic data to estimate disease risk, enable early detection, and support drug discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Genomics company profile β
Rome Therapeutics
HQ: United States
Website
- Description: Provider of novel therapies for cancer and autoimmune diseases harnessing the repeatome, including development of LINE-1 reverse transcriptase inhibitors for autoimmune diseases, supported by a data science platform that identifies active elements in the dark genome and assesses their roles in disease to guide drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Rome Therapeutics company profile β
Ethris
HQ: Germany
Website
- Description: Provider of mRNA therapeutics and LNP delivery solutions focused on respiratory diseases and vaccines. Offers the SNIM RNA platform for stabilized non-immunogenic mRNA therapies and the SNaP LNP platform for targeted, inhalable delivery. Pipeline includes ETH47, ETH42, and ETH45 for respiratory indications. Provides in-house and partnered manufacturing with HPLC-free processes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Ethris company profile β
Dicerna
HQ: United States
Website
- Description: Provider of biotechnology research focused on discovering and developing RNA interference (RNAi)-based treatments for rare inherited liver diseases, cancers, and other liver-related conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Dicerna company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Syros
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Syros
2.2 - Growth funds investing in similar companies to Syros
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Syros
4.2 - Public trading comparable groups for Syros
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β